Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Mark Denison and Sarah Leist.
Mark Denison
Connection Strength
0.265
Sarah Leist
  1. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020 10; 586(7830):567-571.
    View in: PubMed
    Score: 0.056
  2. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020 07 21; 32(3):107940.
    View in: PubMed
    Score: 0.056
  3. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 04 29; 12(541).
    View in: PubMed
    Score: 0.055
  4. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 01 10; 11(1):222.
    View in: PubMed
    Score: 0.054
  5. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 06 28; 9(396).
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.